Merit Medical Systems Stock News

Merit Medical has been posting healthy revenue growth and should see a pickup in oncology and cardiology procedures as hospitals work through their elective procedure backlogs.

Merit Medical Systems Inc (NASDAQ: MMSI ) is exploring options that include an outright sale to a private equity firm, Reuters reported citing people familiar with the matter . The U.S. medical device manufacturer has an enterprise value of approximately $3.9 billion. The sources said that Merit Medical is working with an investment bank … Full story available on Benzinga.com

Merit Medical (MMSI) rose 4.2% on a report that the medical device maker is said to be exploring options, including a potential sale to a private equity firm.Merit Medical (MMSI) is…

Receipt of the Breakthrough Device Designation for Merit Medical's (MMSI) Embosphere Microspheres is expected to improve patient outcome.

Merit Medical <>, a company focused on disposable medical devices, announced on Monday that the U.S

SOUTH JORDAN, Utah, March 07, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), announced today that it has received “breakthrough device designation” from the U.S. Food & Dru

SOUTH JORDAN, Utah, March 07, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), announced today that it has received “breakthrough device designation” from the U.S. Food & Drug Administration (FDA) for Embosphere® Microspheres for the Genicular Artery Embolization (GAE) indication.

SOUTH JORDAN, Utah, March 07, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI ), announced today that it has received "breakthrough device designation" from the U.S. Food & Drug Administration (FDA) for Embosphere® Microspheres for the Genicular Artery Embolization (GAE) indication. GAE is a procedure intended to reduce pain and disability caused by knee osteoarthritis by reducing blood flow to the knee, minimizing the inflammatory process. As a market-leading solution in embolotherapy, Embosphere Microspheres are the most clinically utilized and clinically studied spherical embolic. With more than 20 years of clinical experience, Embosphere Microspheres have been used in more than 250,000 procedures and featured in more than 200 clinical articles. The FDA Breakthrough Devices Program is intended to provide patients and healthcare providers with more timely access to breakthrough technologies that have the potential for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.

Merit Medical Systems' (MMSI) CEO Fred Lampropoulos on Q4 2021 Results - Earnings Call Transcript

Merit Medical (MMSI) delivered earnings and revenue surprises of 42% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical Systems press release (MMSI): Q4 Non-GAAP EPS of $0.71 beats by $0.20.Revenue of $278.5M (+7.9% Y/Y) beats by $7.54M.FY22 Outlook: Net revenue in the range of…